intratect 100 g/l
biotest pharma gmbh - germania - imunoglobulina normala pt. adm. intravasculara - sol. perf. - 100g/l - imunoglobuline imunoglobulina umana de origine umana
octagam 10 % 100 mg/ml soluţie perfuzabilă
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - soluţie perfuzabilă - 100 mg/ml
octagam 10 % 100 mg/ml soluţie perfuzabilă
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - soluţie perfuzabilă - 100 mg/ml
octagam 10 % 100 mg/ml soluţie perfuzabilă
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - soluţie perfuzabilă - 100 mg/ml
octagam 10 % 100 mg/ml soluţie perfuzabilă
octapharma pharmazeutika produktionsges. m.b.h - immunoglobulinum umane - soluţie perfuzabilă - 100 mg/ml
panzyga 100 mg/ml
octapharma (ip) limited - franta - imunoglobulina normala pt. adm. intravasculara - sol. perf. - 100mg/ml - imunoglobuline imunoglobulina umana de origine umana
octagam 10%
octapharma pharmazeutika produktionsges m.b.h. - austria - imunoglobulina normala pt. adm. intravasculara - sol. perf. - 100 mg/ml - imunoglobuline imunoglobulina umana de origine umana
immunorel solutie perfuzabila 5%
reliance life sciences pvt. ltd. - immunoglobulinum umane - solutie perfuzabila - 5%
immunorel solutie perfuzabila 5%
reliance life sciences pvt. ltd. - immunoglobulinum umane - solutie perfuzabila - 5%
flebogamma dif (previously flebogammadif)
instituto grifols s.a. - imunoglobulina umană normală - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - seruri imune și imunoglobuline, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.